{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:53:20Z","timestamp":1792166000917,"version":"4.4.0"},"reference-count":58,"publisher":"Impact Journals, LLC","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,10]]},"DOI":"10.18632\/oncotarget.19285","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T10:10:41Z","timestamp":1500286241000},"page":"82144-82155","source":"Crossref","is-referenced-by-count":48,"title":["Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration"],"prefix":"10.18632","volume":"8","author":[{"given":"Asfar S.","family":"Azmi","sequence":"first","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfana","family":"Muqbil","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Aboukameel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Senapedis","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc., Newton Centre, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkan","family":"Baloglu","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc., Newton Centre, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Landesman","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc., Newton Centre, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Shacham","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc., Newton Centre, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Kauffman","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc., Newton Centre, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Philip","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi M.","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Jemal","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Matrisian","year":"2014","journal-title":"Cancer Res"},{"key":"3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Jemal","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"4","doi-asserted-by":"crossref","first-page":"16077","DOI":"10.1038\/srep16077","article-title":"Targeting the nuclear export protein XPO1\/CRM1 reverses epithelial to mesenchymal transition","volume":"5","author":"Mohammad","year":"2015","journal-title":"Sci Rep"},{"key":"5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/bjc.2014.260","article-title":"KPT-330 has antitumour activity against non-small cell lung cancer","volume":"111","author":"Koeffler","year":"2014","journal-title":"Br J Cancer"},{"key":"6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1535-7163.MCT-13-0416","article-title":"XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer","volume":"13","author":"Altura","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2012.10.036","article-title":"Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice","volume":"144","author":"Mohammad","year":"2013","journal-title":"Gastroenterology"},{"key":"8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.canlet.2016.09.016","article-title":"Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone","volume":"383","author":"Mohammad","year":"2016","journal-title":"Cancer Lett"},{"key":"9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.chembiol.2014.11.015","article-title":"Identifying drug-target selectivity of small-molecule CRM1\/XPO1 inhibitors by CRISPR\/Cas9 genome editing","volume":"22","author":"Daelemans","year":"2015","journal-title":"Chem Biol"},{"key":"10","doi-asserted-by":"crossref","first-page":"e15115","DOI":"10.1200\/jco.2013.31.15_suppl.e15115","article-title":"CRM1 expression in pancreatic carcinoma","volume":"31","author":"Malafa","year":"2013","journal-title":"JCO"},{"key":"11","doi-asserted-by":"crossref","first-page":"21655","DOI":"10.1073\/pnas.0912384106","article-title":"CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs","volume":"106","author":"Rossi","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/gtc.12218","article-title":"Exportin-5 mediates nuclear export of SRP RNA in vertebrates","volume":"20","author":"Ohno","year":"2015","journal-title":"Genes Cells"},{"key":"13","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2174\/1389450111314100002","article-title":"Nuclear export mediated regulation of microRNAs: potential target for drug intervention","volume":"14","author":"Azmi","year":"2013","journal-title":"Curr Drug Targets"},{"key":"14","doi-asserted-by":"crossref","first-page":"44312","DOI":"10.1074\/jbc.M307089200","article-title":"Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells","volume":"278","author":"Dutta","year":"2003","journal-title":"J Biol Chem"},{"key":"15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2619","article-title":"MicroRNAs\u2014the micro steering wheel of tumour metastases","volume":"9","author":"Calin","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"16","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1056\/NEJMp058190","article-title":"MicroRNAs as oncogenes and tumor suppressors","volume":"353","author":"Chen","year":"2005","journal-title":"N Engl J Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Croce","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Pichiorri","year":"2005","journal-title":"N Engl J Med"},{"key":"19","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1073\/pnas.0510565103","article-title":"A microRNA expression signature of human solid tumors defines cancer gene targets","volume":"103","author":"Lanza","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000113489","article-title":"Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer","volume":"72","author":"Vyzula","year":"2007","journal-title":"Oncology"},{"key":"21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.bjc.6605742","article-title":"The functional significance of microRNA-145 in prostate cancer","volume":"103","author":"Dahiya","year":"2010","journal-title":"Br J Cancer"},{"key":"22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/MPA.0b013e3182592ba7","article-title":"Expression of microRNAs in patients with pancreatic cancer and its prognostic significance","volume":"42","author":"Voros","year":"2013","journal-title":"Pancreas"},{"key":"23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.bbrc.2013.10.053","article-title":"MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1","volume":"441","author":"Hao","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.canlet.2013.03.003","article-title":"MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer","volume":"335","author":"Nam","year":"2013","journal-title":"Cancer Lett"},{"key":"25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12935-016-0331-4","article-title":"MiR-145 functions as a tumor suppressor via regulating angiopoietin-2 in pancreatic cancer cells","volume":"16","author":"Zhu","year":"2016","journal-title":"Cancer Cell Int"},{"key":"26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11605-016-3222-z","article-title":"Restitution of tumor suppressor microRNA-145 using magnetic nanoformulation for pancreatic cancer therapy","volume":"21","author":"Chauhan","year":"2017","journal-title":"J Gastrointest Surg"},{"key":"27","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1101\/gad.1950610","article-title":"Repression of the miR-143\/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway","volume":"24","author":"Mendell","year":"2010","journal-title":"Genes Dev"},{"key":"28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/0008-5472.CAN-09-2021","article-title":"MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1","volume":"70","author":"Mo","year":"2010","journal-title":"Cancer Res"},{"key":"29","doi-asserted-by":"publisher","first-page":"10816","DOI":"10.18632\/oncotarget.2522","article-title":"miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma","volume":"5","author":"Kong","year":"2014","journal-title":"Oncotarget"},{"key":"30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4161\/rna.8.1.14259","article-title":"MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1","volume":"8","author":"Au","year":"2011","journal-title":"RNA Biol"},{"key":"31","first-page":"1328","article-title":"MicroRNA-145 suppresses cell migration and invasion by targeting paxillin in human colorectal cancer cells","volume":"8","author":"Wang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"32","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.febslet.2014.02.054","article-title":"MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer","volume":"588","author":"Liu","year":"2014","journal-title":"FEBS Lett"},{"key":"33","first-page":"3106","article-title":"miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition","volume":"8","author":"Shen","year":"2016","journal-title":"Am J Transl Res"},{"key":"34","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.18632\/oncotarget.6499","article-title":"Targeting oncogenic PLCE1 by miR-145 impairs tumor proliferation and metastasis of esophageal squamous cell carcinoma","volume":"7","author":"Hu","year":"2016","journal-title":"Oncotarget"},{"key":"35","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1007\/s13277-015-4462-3","article-title":"MiR-145 suppresses cell proliferation and motility by inhibiting ROCK1 in hepatocellular carcinoma","volume":"37","author":"Wang","year":"2016","journal-title":"Tumour Biol"},{"key":"36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-014-2495-8","article-title":"KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma","volume":"74","author":"Koeffler","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"37","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/leu.2014.9","article-title":"Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells","volume":"28","author":"Andritsos","year":"2014","journal-title":"Leukemia"},{"key":"38","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1186\/s12885-015-1936-z","article-title":"KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models","volume":"15","author":"Festuccia","year":"2015","journal-title":"BMC Cancer"},{"key":"39","doi-asserted-by":"crossref","first-page":"25964","DOI":"10.1074\/jbc.M113.459784","article-title":"Matrix metalloproteinase (MMP)-1 induces lung alveolar epithelial cell migration and proliferation, protects from apoptosis, and represses mitochondrial oxygen consumption","volume":"288","author":"Pardo","year":"2013","journal-title":"J Biol Chem"},{"key":"40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1440-1711.2006.01465.x","article-title":"Membrane type 1-matrix metalloproteinase is involved in the migration of human monocyte-derived dendritic cells","volume":"84","author":"Lu","year":"2006","journal-title":"Immunol Cell Biol"},{"key":"41","doi-asserted-by":"crossref","first-page":"e0155264","DOI":"10.1371\/journal.pone.0155264","article-title":"Kaempferol inhibits pancreatic cancer cell growth and migration through the blockade of EGFR-related pathway","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"42","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/ijc.25284","article-title":"miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma","volume":"127","author":"Matsubara","year":"2010","journal-title":"Int J Cancer"},{"key":"43","first-page":"701","article-title":"Paradoxical role of SOX2 in gastric cancer","volume":"6","author":"Ribeiro","year":"2016","journal-title":"Am J Cancer Res"},{"key":"44","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","article-title":"MYC, metabolism, and cancer","volume":"5","author":"Dang","year":"2015","journal-title":"Cancer Discov"},{"key":"45","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MPA.0000000000000276","article-title":"The role of p21-activated kinases in pancreatic cancer","volume":"44","author":"Nikfarjam","year":"2015","journal-title":"Pancreas"},{"key":"46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/07357907.2015.1025407","article-title":"Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression","volume":"33","author":"Ittmann","year":"2015","journal-title":"Cancer Invest"},{"key":"47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7785\/tcrt.2012.500367","article-title":"MicroRNA-145 function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer","volume":"13","author":"Wang","year":"2014","journal-title":"Technol Cancer Res Treat"},{"key":"48","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.bbrc.2012.06.123","article-title":"MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells","volume":"427","author":"Zheng","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"49","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1089\/hum.2008.134","article-title":"let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibitscell proliferation but fails to alter tumor progression","volume":"20","author":"Cordelier","year":"2009","journal-title":"Hum Gene Ther"},{"key":"50","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00428-010-1030-5","article-title":"Frequent concomitant inactivation of miR-34a and miR-34b\/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas","volume":"458","author":"Hermeking","year":"2011","journal-title":"Virchows Arch"},{"key":"51","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.febslet.2009.10.007","article-title":"Let-7a elevates p21(WAF1) levels by targeting of NIRF and suppresses the growth of A549 lung cancer cells","volume":"583","author":"Peng","year":"2009","journal-title":"FEBS Lett"},{"key":"52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11418-016-1024-y","article-title":"AU-1 from Agavaceae plants causes transient increase in p21\/Cip1 expression in renal adenocarcinoma ACHN cells in an miR-34-dependent manner","volume":"71","author":"Hayakawa","year":"2017","journal-title":"J Nat Med"},{"key":"53","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/pbc.25727","article-title":"Pharmacodynamic and genomic markers associated with response to the XPO1\/CRM1 inhibitor selinexor (KPT-330): a report from the pediatric preclinical testing program","volume":"63","author":"Lyalin","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"54","doi-asserted-by":"crossref","first-page":"e102983","DOI":"10.1371\/journal.pone.0102983","article-title":"Novel small molecule XPO1\/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells","volume":"9","author":"Lesinski","year":"2014","journal-title":"PLoS One"},{"key":"55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12885-016-2061-3","article-title":"Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer","volume":"16","author":"Zienolddiny","year":"2016","journal-title":"BMC Cancer"},{"key":"56","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4049\/jimmunol.1301397","article-title":"The p53 transcription factor modulates microglia behavior through microRNA-dependent regulation of c-Maf","volume":"192","author":"Garden","year":"2014","journal-title":"J Immunol"},{"key":"57","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.18632\/oncotarget.1813","article-title":"Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer","volume":"5","author":"Mohammad","year":"2014","journal-title":"Oncotarget"},{"key":"58","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/1535-7163.MCT-15-0104","article-title":"Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer","volume":"14","author":"Mahipal","year":"2015","journal-title":"Mol Cancer Ther"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T13:10:58Z","timestamp":1589202658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":58,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2017,10,10]]}},"alternative-id":["19285","29137251"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19285","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,17]]}}}